Hims & Hers

Hims & Hers sells health care the way a subscription box sells razors. Its telehealth platform connects people to online consultations and then ships prescription and over-the-counter treatments directly to their door, focused on conditions many patients would rather not discuss in person: hair loss, erectile dysfunction, skin care, mental health and, more recently, weight loss. That direct-to-consumer model, marketed heavily under the hims and hers brands, has driven fast subscriber growth. Founded in 2017 and based in San Francisco, the company rode the GLP-1 weight-loss wave by offering compounded versions of the drugs, a business that boosted growth but also drew regulatory and legal risk. The stock is a high-growth, high-volatility bet on consumer telehealth: bulls point to its expanding subscriber base and new treatment categories, while skeptics question margins, drug-supply dependence and how durable the weight-loss revenue will prove.

On MyRWA, HIMS trades tokenized across 21 on-chain venues - see the listings below.